AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35943380 — intervention group
Group type: EXPERIMENTAL
Intervention: iTRAC intervention (4-module digital intervention)
Number of subjects: 85
Study 35943380 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 85
Study 33607792 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection (PAI) of multimodal drugs
Number of subjects: 56
Study 33607792 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 56
Study 32251249 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plate with addition of a dorsal‐ulnar pin plate
Number of subjects: 18
Study 32251249 — intervention group
Group type: COMPARATOR
Intervention: Volar plate only
Number of subjects: 18
Study 35938544 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 35938544 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 34160391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth breast shield after the scout view
Number of subjects: 3
Study 34160391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth breast shield before the scout view
Number of subjects: 3
Study 34160391 — intervention group
Group type: COMPARATOR
Intervention: No shielding
Number of subjects: 3
Study 32745667 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased planned radiotherapy dose (>55 Gy) in a small rectal volume adjacent to the clinical target volume.
Number of subjects: 1286
Study 32745667 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased low-intermediate planned radiotherapy dose (∼25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS).
Number of subjects: 1286
Study 35765223 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of mecobalamin at Zusanli (S36)
Number of subjects: 40
Study 35765223 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of mecobalamin
Number of subjects: 40
Study 34068437 — intervention group
Group type: EXPERIMENTAL
Intervention: FV intervention arm (2 h workshop on increasing FV consumption and related food literacy)
Number of subjects: 803
Study 34068437 — intervention group
Group type: COMPARATOR
Intervention: More appreciation control arm (2 h workshop on increasing appreciation of children)
Number of subjects: 803
Study 34068437 — intervention group
Group type: COMPARATOR
Intervention: Less criticism control arm (2 h workshop on reducing criticism of children)
Number of subjects: 803
Study 34068437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (FV and MALC)
Number of subjects: 803
Study 33603241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Number of subjects: 44
Study 33603241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 44
Study 35503746 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator overdenture (LOD)
Number of subjects: 18
Study 35503746 — intervention group
Group type: COMPARATOR
Intervention: Ball overdenture (BOD)
Number of subjects: 18
Study 36413710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib and dexamethasone (D-Vd)
Number of subjects: 0
Study 36413710 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 0
Study 33592132 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake (salami)
Number of subjects: 12
Study 33592132 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual intake of sausages
Number of subjects: 12
Study 33592132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total processed meat intake
Number of subjects: 12
Study 32795162 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk extensor stimulation during sudden stops events
Number of subjects: 6
Study 32795162 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm to detect wheelchair sudden stops
Number of subjects: 6
Study 33484344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pie-crusting technique of the femoral origin of medial collateral ligament (MCL)
Number of subjects: 80
Study 33484344 — intervention group
Group type: COMPARATOR
Intervention: Conventional medial release (classic sub-periosteal release of the tibial insertion of superficial MCL)
Number of subjects: 80
Study 35610157 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Dads in Nutrition Education
Number of subjects: 480
Study 32066032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (66.7% tube load)
Number of subjects: 139
Study 32066032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose CT (33.3% tube load)
Number of subjects: 139
Study 32066032 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (100% tube load)
Number of subjects: 139
Study 34271984 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA) as an add-on to treatment as usual
Number of subjects: 0
Study 34271984 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 32417925 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60
Study 32417925 — intervention group
Group type: COMPARATOR
Intervention: Serratus Anterior Plane Block (SAPB)
Number of subjects: 60
Study 35303255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 36
Study 35303255 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 36
Study 34341035 — intervention group
Group type: EXPERIMENTAL
Intervention: His-Purkinje system pacing (HPSP)
Number of subjects: 46
Study 34341035 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 46
Study 33196739 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,940 nm fractional erbium:YAG laser treatment
Number of subjects: 18
Study 34031053 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole (S-ITZ)
Number of subjects: 0
Study 34031053 — intervention group
Group type: COMPARATOR
Intervention: Conventional itraconazole (C-ITZ)
Number of subjects: 0
Study 32151965 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Self‐management for people with epilepsy and a history of negative health events)
Number of subjects: 120
Study 32151965 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 120
Study 32151965 — intervention group
Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 120
Study 34787930 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life (EOL) conversation with oncologist
Number of subjects: 672
Study 34787930 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of an advance directive (AD)
Number of subjects: 672
Study 34787930 — intervention group
Group type: COMPARATOR
Intervention: No EOL conversation
Number of subjects: 672
Study 34787930 — intervention group
Group type: COMPARATOR
Intervention: No advance directive (AD)
Number of subjects: 672
Study 33530238 — intervention group
Group type: EXPERIMENTAL
Intervention: Short one-on-one nursing intervention
Number of subjects: 0
Study 33530238 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32182226 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory resistance exercise group (n=22)
Number of subjects: 44
Study 32182226 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 44
Study 36416319 — intervention group
Group type: EXPERIMENTAL
Intervention: Biorepair toothpaste (HA-based desensitizing toothpaste)
Number of subjects: 4
Study 36416319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dontodent toothpaste (HA-based desensitizing toothpaste)
Number of subjects: 4
Study 36416319 — intervention group
Group type: EXPERIMENTAL
Intervention: HA paste
Number of subjects: 4
Study 36416319 — intervention group
Group type: COMPARATOR
Intervention: Control (no desensitizing treatment)
Number of subjects: 4
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-RADS criteria for primary site
Number of subjects: 104
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-RADS criteria for neck
Number of subjects: 104
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI of primary site
Number of subjects: 104
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-RADS categories of primary site
Number of subjects: 104
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-RADS categories of neck
Number of subjects: 104
Study 33533989 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-RADS categories 2a, 2b, and 3 of primary site
Number of subjects: 104
Study 32212765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial-language and play condition (n = 26)
Number of subjects: 50
Study 32212765 — intervention group
Group type: COMPARATOR
Intervention: Play-only condition (n = 24)
Number of subjects: 50
Study 33484370 — intervention group
Group type: EXPERIMENTAL
Intervention: MYmind mindfulness program
Number of subjects: 0
Study 33484370 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 34939119 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can Quit (group support + nicotine replacement therapy)
Number of subjects: 194
Study 34939119 — intervention group
Group type: COMPARATOR
Intervention: Individual support delivered by health professionals (Control)
Number of subjects: 194
Study 34145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg orally (group D)
Number of subjects: 70
Study 34145727 — intervention group
Group type: COMPARATOR
Intervention: Starch placebo capsules (group C)
Number of subjects: 70
Study 34883818 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating heel running shoes
Number of subjects: 20
Study 34883818 — intervention group
Group type: COMPARATOR
Intervention: Conventional footwear
Number of subjects: 20
Study 35512259 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month treatment group (FOLFOX or CAPOX)
Number of subjects: 1291
Study 35512259 — intervention group
Group type: COMPARATOR
Intervention: 6-month treatment group (FOLFOX or CAPOX)
Number of subjects: 1291
Study 35512259 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 1291
Study 35512259 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 1291
Study 34670277 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) with BLUE400 filter system
Number of subjects: 162
Study 35778578 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabahn® and Excluder® iliac extension (V-E)
Number of subjects: 0
Study 35778578 — intervention group
Group type: COMPARATOR
Intervention: Two Viabahn® parallel stents (V-V)
Number of subjects: 0
Study 35778578 — intervention group
Group type: EXPERIMENTAL
Intervention: Post dilatation with non-compliant balloon for internal iliac and compliant balloon for external iliac
Number of subjects: 0
Study 35778578 — intervention group
Group type: EXPERIMENTAL
Intervention: Post dilatation with two non-compliant balloons
Number of subjects: 0
Study 33540715 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention involving posters and a web app
Number of subjects: 316
Study 33540715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 316
Study 33660345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic reperfusion (HR) in SHR and ZR
Number of subjects: 106
Study 33660345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic reperfusion (HR) in SHR
Number of subjects: 106
Study 33660345 — intervention group
Group type: COMPARATOR
Intervention: Normoxic reperfusion (NR) in SHR and ZR
Number of subjects: 106
Study 33660345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic reperfusion (HR) in Wistar rats (WR)
Number of subjects: 106
Study 33660345 — intervention group
Group type: COMPARATOR
Intervention: Normoxic reperfusion (NR) in Wistar rats (WR)
Number of subjects: 106
Study 34273635 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ1a + hydroxychloroquine + lopinavir/ritonavir + umifenovir
Number of subjects: 101
Study 34273635 — intervention group
Group type: COMPARATOR
Intervention: IFNβ1a + hydroxychloroquine + lopinavir/ritonavir
Number of subjects: 101
Study 36258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg before anesthesia
Number of subjects: 105
Study 36258848 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules before anesthesia and intravenous Mg sulfate 30 mg/kg during the perioperative period
Number of subjects: 105
Study 36258848 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules before anesthesia and normal intravenous saline during the operation
Number of subjects: 105
Study 34610178 — intervention group
Group type: EXPERIMENTAL
Intervention: Viburnum opulus 1000 mg peroral 3 × 2 and diclofenac 50 mg peroral on-demand
Number of subjects: 86
Study 34610178 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg peroral 1 × 1 and diclofenac 50 mg peroral on-demand
Number of subjects: 86
Study 34610178 — intervention group
Group type: EXPERIMENTAL
Intervention: Viburnum opulus in 5-10 mm stone size subgroup
Number of subjects: 86
Study 34610178 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin in 5-10 mm stone size subgroup
Number of subjects: 86
Study 32151735 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 43
Study 32151735 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Training (TT)
Number of subjects: 43
Study 32151735 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 43
Study 35938329 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-cm moxa stick
Number of subjects: 240
Study 35938329 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cm moxa stick
Number of subjects: 240
Study 35938329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cm moxa stick
Number of subjects: 240
Study 35938329 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 240
Study 34784991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy intervention (Recovery through Group Study - ReGroup)
Number of subjects: 203
Study 34548367 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of 250 mg 17-hydroxyprogesterone caproate
Number of subjects: 1355
Study 34548367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1355
Study 35621073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (160 mg) administered via nasogastric tube twice a day for 10 days
Number of subjects: 40
Study 35621073 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered via nasogastric tube twice a day for 10 days
Number of subjects: 40
Study 32239161 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening sleep disturbance
Number of subjects: 599
Study 32239161 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent sleep disturbance
Number of subjects: 599
Study 32239161 — intervention group
Group type: COMPARATOR
Intervention: Improving sleep
Number of subjects: 599
Study 35482076 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 78
Study 35482076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 34224267 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive blood transfusion strategy
Number of subjects: 0
Study 34224267 — intervention group
Group type: COMPARATOR
Intervention: Liberal blood transfusion strategy
Number of subjects: 0
Study 36129698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready2Change telephone-delivered intervention (4 to 6 sessions with a psychologist)
Number of subjects: 344
Study 36129698 — intervention group
Group type: COMPARATOR
Intervention: Active control (four 5-minute telephone check-ins and pamphlets)
Number of subjects: 344
Study 32320797 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium Respimat 5 μg once daily added to high-dose ICS plus long-acting β2-agonist (severe asthma)
Number of subjects: 0
Study 32320797 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium Respimat 2.5 or 5 μg once daily added to medium-dose ICS (moderate asthma)
Number of subjects: 0
Study 32320797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat (both dosages)
Number of subjects: 0
Study 35760720 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks)
Number of subjects: 372
Study 35760720 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly)
Number of subjects: 372
Study 35760720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 32929910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid sequential rivaroxaban
Number of subjects: 69
Study 32929910 — intervention group
Group type: COMPARATOR
Intervention: Simple rivaroxaban (Control)
Number of subjects: 69
Study 35869634 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplontersen
Number of subjects: 0
Study 35869634 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplontersen (injection into abdomen)
Number of subjects: 0
Study 33140841 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient (OP) setting
Number of subjects: 113
Study 33140841 — intervention group
Group type: COMPARATOR
Intervention: Inpatient (IP) setting
Number of subjects: 113
Study 33140841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during IOL
Number of subjects: 113
Study 33140841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum experience questionnaire
Number of subjects: 113
Study 33140841 — intervention group
Group type: EXPERIMENTAL
Intervention: Future choice of catheter IOL
Number of subjects: 113
Study 35152311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented standard femoral stem (group 1)
Number of subjects: 24
Study 35152311 — intervention group
Group type: EXPERIMENTAL
Intervention: Long femoral stem (group 2)
Number of subjects: 24
Study 34292336 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone plus bone resorption inhibitors (BRIs)
Number of subjects: 745
Study 34292336 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate with prednisone alone
Number of subjects: 745
Study 34292336 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone plus BRIs
Number of subjects: 745
Study 34292336 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone plus BRIs (low-volume disease subgroup)
Number of subjects: 745
Study 32931996 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 57
Study 32931996 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 57
Study 616490283 — intervention group
Group type: EXPERIMENTAL
Intervention: 90‐minute nap opportunity
Number of subjects: 95
Study 616490283 — intervention group
Group type: COMPARATOR
Intervention: Quiet wakefulness
Number of subjects: 95
Study 35880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (30 min, 3 times per week for 12 weeks) at acupoints including Baihui (GV20), Zhongwan (CV12), Shenting (GV24), Shenshu (BL23), Ciliao (BL32)
Number of subjects: 12
Study 35880279 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 12
Study 35880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 12
Study 32597548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment (IT)
Number of subjects: 164
Study 32597548 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 164
Study 32597548 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 164
Study 32597548 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in serum low-density lipoprotein cholesterol level
Number of subjects: 164
Study 32809099 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal mixed models (LMM)
Number of subjects: 7
Study 32809099 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal partial credit model (LPCM)
Number of subjects: 7
Study 32809099 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-event models for time to deterioration (TTD/TUDD)
Number of subjects: 7
Study 32809099 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item scales using LPCM
Number of subjects: 7
Study 32962406 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol/kg/min)
Number of subjects: 44
Study 32962406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (8 pmol/kg/min)
Number of subjects: 44
Study 34369914 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 74
Study 34369914 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth+ (with virtual visits)
Number of subjects: 74
Study 34369914 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 74
Study 36361390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group (VG) - 20 minutes of vibration (frequency: 30 Hz, amplitude: 5 mm) and 40 minutes of conventional exercise
Number of subjects: 31
Study 36361390 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - 60 minutes of conventional exercise only
Number of subjects: 31
Study 33115545 — intervention group
Group type: EXPERIMENTAL
Intervention: ItFits-toolkit
Number of subjects: 12
Study 33115545 — intervention group
Group type: COMPARATOR
Intervention: Implementation-as-usual activities
Number of subjects: 12
Study 35751945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention with external facilitation for local change team activities
Number of subjects: 14012
Study 35751945 — intervention group
Group type: COMPARATOR
Intervention: Core intervention with encouragement to form interagency workgroups
Number of subjects: 14012
Study 33999548 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin per day
Number of subjects: 15076
Study 33999548 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin per day
Number of subjects: 15076
Study 33077258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nintedanib (BIBF 1120) with oral cyclophosphamide (100 mg o.d.)
Number of subjects: 117
Study 33077258 — intervention group
Group type: COMPARATOR
Intervention: Placebo with oral cyclophosphamide (100 mg o.d.)
Number of subjects: 117